| Literature DB >> 26376979 |
Sang Mi Yuk1,2, Kyu-Tae Han3,4, Sun Jung Kim5, Woorim Kim6,7, Tae Yong Sohn8, Byungyool Jeon9, Young-Man Kim10, Eun-Cheol Park11,12.
Abstract
BACKGROUND: In the year 2000, the South Korean government introduced a program for separation of drug prescribing and dispensing. The goals of the program are to reduce misuse of drugs and to contain drug expenditures. The government also designated exception regions for the program to reduce the inconvenience for people who reside in areas with a shortage of health care resources. However, according to government reports, many adverse events related to drug misuse occurred in these exception regions after the program reforms were introduced. Therefore, it is worth investigating the factors that relate to drug consumption so that misuse in exception regions can be reduced.Entities:
Mesh:
Year: 2015 PMID: 26376979 PMCID: PMC4572639 DOI: 10.1186/s13011-015-0032-3
Source DB: PubMed Journal: Subst Abuse Treat Prev Policy ISSN: 1747-597X
Fig. 1Sampling method for data used in this study
General characteristics of pharmacists and pharmacies
| Variables | Separation of drug prescribing and dispensing (N=16,455) | Test statistics (df) |
| |||
|---|---|---|---|---|---|---|
| Exception | Application | |||||
| N/Mean | %/SD | N/Mean | %/SD | |||
| Pharmacy characteristics | ||||||
| Sex of pharmacist | ||||||
| Male | 224 | 72.5 | 8,036 | 49.8 |
| |
| Female | 85 | 27.5 | 8,110 | 50.2 | ||
| Age of pharmacist (years) | ||||||
| ≤45 | 27 | 8.7 | 4,890 | 30.3 |
| <.0001a |
| 46–55 | 51 | 16.5 | 4,367 | 27.1 | ||
| 56–65 | 74 | 24 | 3,268 | 20.2 | ||
| ≥66 | 157 | 50.8 | 3,621 | 22.4 | ||
| Length of Operation | ||||||
| ≤12 months | 48 | 15.5 | 2,329 | 14.4 |
| 0.067a |
| 13–24 months | 49 | 15.9 | 1,914 | 11.9 | ||
| ≥25 months | 212 | 68.6 | 11,903 | 73.7 | ||
| Period of exclusion for reformed program | ||||||
| ≤18 months | 95 | 30.7 | 16,146 | 100 |
| <.0001a |
| ≥19 months | 214 | 69.3 | 0 | 0 | ||
| Total pharmacy cost for drug purchase (10 million KRW) | 18.0 | ±19.1 | 75.0 | ±75.2 | Z=−18.7 | <.0001b |
| Regional Characteristics | ||||||
| Region | ||||||
| Metropolitan (N=74) | 14 | 4.5 | 8,134 | 50.4 |
| <.0001a |
| Non-metropolitan (N=173) | 295 | 95.5 | 8,012 | 49.6 | ||
| Total number of clinics in regions with pharmacies | ||||||
| ≤60 (N=212) | 304 | 98.4 | 11,961 | 74.1 |
| |
| ≥61 (N=35) | 5 | 1.6 | 4,185 | 25.9 | ||
| Total number of pharmacies in regions with pharmacies | ||||||
| ≤45 (N=176) | 273 | 88.4 | 10,606 | 65.7 |
| |
| ≥46 (N=71) | 36 | 11.7 | 5,540 | 34.3 | ||
| Average per capita income in regions with pharmacies | ||||||
| ≤38 million KRW (N=175) | 232 | 75.1 | 8,442 | 52.3 |
| |
| ≥39 million KRW (N=72) | 77 | 24.9 | 7,704 | 47.7 | ||
| Proportion of national basic livelihood security beneficiaries in regions with pharmacies | 3.2 | ±1.6 | 2.9 | ±1.5 | Z=3.7 | 0.0002b |
| Total | 309 | 1.9 | 16,146 | 98.1 | ||
Note. Significant level P < 0.05. If these values were lower than 0.05, it indicated that the distribution or mean/standard deviation of each independent variable were differenced by separation of drug prescribing and dispensing. KRW Republic of Korea Won, df degrees of freedom
aP for Chi-square test, Chi-square tests were used to examine the differences in distribution of each categorical variable by separation of drug prescribing and dispensing
bp for Mann–Whitney U test, Mann–Whitney U tests were used to examine differences in mean/standard deviation of each continuous variable by separation of drug prescribing and dispensing
Percentages of drug consumption categorized by pharmacist and pharmacy variables, by four drug categories
| Variables | Antipyretic; Analgesic; | Psychotropic drugs | Adrenal cortical hormones | Antibiotics | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-inflammatory drugs | ||||||||||||||||
| Mean | SD | Test statistics (df) |
| Mean | SD | Test statistics (df) |
| Mean | SD | Test statistics (df) |
| Mean | SD | Test statistics (df) |
| |
| Pharmacy characteristics | ||||||||||||||||
| Sex of pharmacist | ||||||||||||||||
| Male | 9.86 | 9.46 | Z = −11.6574 | <.0001† | 0.82 | 2.35 | Z = 4.6 | <.0001† | 0.29 | 0.71 | Z = −3.3 | 0.0021† | 6.77 | 30.87 | Z = 7.9 | <.0001† |
| Female | 9.03 | 6.46 | 0.91 | 2.47 | 0.28 | 0.68 | 7.24 | 8.71 | ||||||||
| Age of pharmacist (years) | ||||||||||||||||
| ≤45 | 9.20 | 11.17 | X2(3) = 382.8 | <.0001a | 0.95 | 2.63 | X2(3) = 207.2 | <.0001a | 0.32 | 0.73 | X2(3) = 85.1 | <.0001a | 8.90 | 32.82 | X2(3) = 378.3 | <.0001a |
| 46–55 | 8.72 | 5.99 | 0.98 | 2.35 | 0.26 | 0.55 | 7.00 | 7.96 | ||||||||
| 56–65 | 9.30 | 5.88 | 0.89 | 2.68 | 0.26 | 0.60 | 6.01 | 9.07 | ||||||||
| ≥66 | 10.75 | 7.04 | 0.60 | 1.83 | 0.30 | 0.87 | 5.44 | 26.32 | ||||||||
| Length of operation | ||||||||||||||||
| ≤12 months | 9.94 | 15.77 | X2(2) = 1.4 | 0.3231a | 0.92 | 2.67 | X2(2) = 8.2 | 0.0109a | 0.35 | 0.96 | X2(2) = 18.4 | <.0001a | 10.45 | 56.56 | X2(2) = 173.7 | <.0001a |
| 13–24 months | 9.64 | 6.25 | 0.86 | 2.02 | 0.33 | 0.78 | 7.99 | 8.58 | ||||||||
| ≤25 months | 9.32 | 5.86 | 0.86 | 2.41 | 0.27 | 0.62 | 6.17 | 7.66 | ||||||||
| Separation of drug prescribing and dispensing | ||||||||||||||||
| Exception | 15.21 | 6.31 | Z = 18.5 | <.0001† | 0.39 | 1.08 | Z = −15.2 | <.0001† | 1.09 | 1.55 | Z = 14.0 | <.0001† | 6.01 | 8.81 | Z = 2.3 | 0.0232† |
| Application | 9.34 | 8.11 | 0.88 | 2.42 | 0.27 | 0.66 | 7.03 | 22.91 | ||||||||
| Period of exclusion for reformed program | ||||||||||||||||
| ≤18 months | 9.36 | 8.11 | Z = 16.8 | <.0001† | 0.87 | 2.42 | Z = −14.1 | <.0001† | 0.28 | 0.67 | Z = 12.2 | <.0001† | 7.02 | 22.87 | Z = 2.8 | 0.0057† |
| ≥19 months | 15.69 | 5.63 | 0.34 | 1.12 | 1.10 | 1.57 | 5.76 | 3.61 | ||||||||
| Regional characteristics | ||||||||||||||||
| Region | ||||||||||||||||
| Metropolitan | 9.12 | 6.23 | Z = −10.5 | <.0001† | 0.86 | 2.60 | Z = −8.1 | <.0001† | 0.26 | 0.63 | Z = −11.3 | <.0001† | 7.00 | 19.34 | Z = −2.0 | 0.0404† |
| Non-metropolitan | 9.77 | 9.61 | 0.88 | 2.20 | 0.32 | 0.76 | 7.02 | 25.61 | ||||||||
| Total number of clinics in regions with pharmacies | ||||||||||||||||
| ≤60 | 9.53 | 6.19 | Z = −7.5 | <.0001† | 0.86 | 2.44 | Z = −3.1 | 0.0020† | 0.29 | 0.71 | Z = −6.5 | <.0001† | 6.99 | 16.42 | Z = −3.7 | 0.† |
| ≥61 | 9.21 | 12.1 | 0.89 | 2.29 | 0.27 | 0.66 | 7.05 | 35.20 | ||||||||
| Total number of pharmacies in region with pharmacies | ||||||||||||||||
| ≤45 | 9.45 | 6.20 | Z = −2.2 | 0.0296† | 0.88 | 2.57 | Z = 0.2 | 0.8213† | 0.30 | 0.69 | Z = −9.2 | <.0001† | 7.30 | 16.90 | Z = −13.3 | <.0001† |
| ≥46 | 9.45 | 10.93 | 0.85 | 2.06 | 0.26 | 0.71 | 6.44 | 31.08 | ||||||||
| Average per capita income in regions with pharmacies | ||||||||||||||||
| ≤38 million KRW | 9.77 | 9.48 | Z = −9.2 | <.0001† | 0.87 | 2.22 | Z = −9.6 | <.0001† | 0.29 | 0.69 | Z = −4.5 | <.0001† | 6.55 | 25.65 | Z = 11.3 | <.0001† |
| ≥39 million KRW | 9.09 | 6.23 | 0.87 | 2.59 | 0.28 | 0.71 | 7.52 | 18.92 | ||||||||
| Total | 9.40 | 8.10 | 0.90 | 2.40 | 0.30 | 0.70 | 7.00 | 22.70 | ||||||||
Note. Significant level P < 0.05. If these values were lower than 0.05, it indicated that the mean/standard deviation of drug consumption were differenced by each independent variable. KRW Republic of Korea Won, df degrees of freedom
†p for Mann–Whitney U test, Mann–Whitney U tests were used to examine differences in mean/standard deviation of drug consumption by each categorical variable as these did not have normal distribution and below than 3 groups
ap for Kruskal-Wallis test, Kruskal-Wallis tests were used to examine differences in mean/standard deviation of drug consumption by each categorical variable as these did not have normal distribution and above than 3 groups
Results for multi-level analyses of the associations with percentages of drug consumption in Antipyretic; Analgesic; Anti-inflammatory drugs
| Variables | Antipyretic; Analgesic; Anti-inflammatory drugs | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | |||||||||||||||||
| β | SE | t | df |
| β | SE | t | df |
| β | SE | t | df |
| β | SE | t | df |
| |
| Intercept | 9.51 | 0.08 | 120.05 | 246 | <.0001 | 12.68 | 0.99 | 12.80 | 246 | <.0001 | 9.23 | 0.27 | 34.53 | 241 | <.0001 | 12.26 | 1.02 | 12.03 | 241 | <.0001 |
| Pharmacy characteristics | ||||||||||||||||||||
| Sex of pharmacist | ||||||||||||||||||||
| Male | 0.64 | 0.13 | 5.00 | 243 | <.0001 | 0.52 | 0.13 | 4.03 | 243 | <.0001 | ||||||||||
| Female | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Age of pharmacist (years) | ||||||||||||||||||||
| ≤45 | −0.65 | 0.18 | −3.62 | 722 | 0.0003 | −0.66 | 0.18 | −3.65 | 722 | 0.0003 | ||||||||||
| 46–55 | −0.82 | 0.18 | −4.48 | 722 | <.0001 | −0.82 | 0.18 | −4.45 | 722 | <.0001 | ||||||||||
| 56–65 | −0.62 | 0.19 | −3.26 | 722 | 0.0012 | −0.59 | 0.19 | −3.07 | 722 | 0.0022 | ||||||||||
| ≥66 | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Length of operation | ||||||||||||||||||||
| ≤12 months | −1.06 | 0.20 | −5.35 | 454 | <.0001 | −1.08 | 0.20 | −5.47 | 454 | <.0001 | ||||||||||
| 13–24 months | −0.80 | 0.20 | −3.97 | 454 | <.0001 | −0.81 | 0.20 | −4.01 | 454 | <.0001 | ||||||||||
| ≥25 months | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Separation of drug prescribing and dispensing | ||||||||||||||||||||
| Exception | 3.41 | 0.82 | 4.14 | 93 | <.0001 | 3.19 | 0.82 | 3.88 | 93 | 0.0002 | ||||||||||
| Application | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Period of exclusion for reformed program | ||||||||||||||||||||
| ≤18 months | −1.05 | 0.98 | −1.07 | 88 | 0.2860 | −0.93 | 0.98 | −0.95 | 88 | 0.3455 | ||||||||||
| ≥19 months | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Total drug purchase (10 million KRW) | −0.02 | 0.00 | −25.37 | 16,000 | <.0001 | −0.02 | 0.00 | −25.93 | 16,000 | <.0001 | ||||||||||
| Regional characteristics | ||||||||||||||||||||
| Region | ||||||||||||||||||||
| Metropolitan | −0.53 | 0.16 | −3.22 | 241 | 0.0015 | −0.56 | 0.16 | −3.57 | 241 | 0.0004 | ||||||||||
| Non-metropolitan | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Total number of clinics in regions with pharmacies | ||||||||||||||||||||
| ≤60 | 0.21 | 0.21 | 1.03 | 241 | 0.3027 | 0.12 | 0.20 | 0.61 | 241 | 0.5431 | ||||||||||
| ≥61 | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Total number of pharmacy in regions with pharmacies | ||||||||||||||||||||
| ≤45 | −0.18 | 0.19 | −0.92 | 241 | 0.3597 | −0.17 | 0.18 | −0.92 | 241 | 0.3574 | ||||||||||
| ≥46 | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Average of individual income in regions with pharmacies | ||||||||||||||||||||
| ≤38 million KRW | 0.47 | 0.17 | 2.73 | 241 | 0.0067 | 0.43 | 0.16 | 2.63 | 241 | 0.0091 | ||||||||||
| ≥39 million KRW | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Proportion of national basic livelihood security beneficiaries in regions with pharmacies | 0.07 | 0.06 | 1.21 | 241 | 0.2271 | 0.14 | 0.05 | 2.72 | 241 | 0.0070 | ||||||||||
| Random parta | Variance | SE | Z |
| Variance | SE | Z |
| Variance | SE | Z |
| Variance | SD | Z |
| ||||
| Variance of the intercept at the regional level | 0.39 | 0.12 | 3.26 | 0.0005 | 0.35 | 0.11 | 3.26 | 0.0006 | 0.27 | 0.10 | 2.55 | 0.0054 | 0.20 | 0.09 | 2.29 | 0.0111 | ||||
| Variance of the intercept at the pharmacy level | 65.48 | 0.73 | 90.21 | <.0001 | 61.92 | 0.69 | 90.23 | <.0001 | 65.44 | 0.73 | 90.24 | <.0001 | 61.85 | 0.69 | 90.28 | <.0001 | ||||
| ICC | 0.0059 | 0.0055 | 0.0040 | 0.0032 | ||||||||||||||||
Note. The results of multilevel linear regression analysis using mixed model to examine associations between program designation (i.e., exception region or application region) and percentages of drug consumption (antipyretic, analgesic, anti-inflammatory drugs, and psychotropic drugs, adrenal cortical hormones, and antibiotics) in hierarchical data which was consisted of pharmacy and regional levels. Significant level P < 0.05. If these values were lower than 0.05, it indicated that there were statistically significant associations between independent variable and drug consumption
Model 1 = empty model, Model 2 = only adjusted for pharmacy-level variables, Model 3 = only adjusted regional-level variables, Model 4 = fully adjusted
KRW Republic of Korea Won, ICC Intra-class Correlation Coefficient, the results were rounded to the second digit after the decimal point, df degrees of freedom
aIf p-value were lower than 0.05, it indicated that each level variable had statistically significant association with the outcome variables. The ICC was defined that the ratio of the between cluster variance to the total variance. It was interpreted as the correlation among observations within the same cluster
Results for multi-level analyses of the associations with percentages of drug consumption in Psychotropic drugs
| Variables | Psychotropic drugs | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | |||||||||||||||||
| β | SE | t | df |
| β | SE | t | df |
| β | SE | t | df |
| β | SE | t | df |
| |
| Intercept | 0.86 | 0.02 | 36.54 | 246 | <.0001 | 0.38 | 0.30 | 1.27 | 246 | 0.2040 | 0.89 | 0.09 | 10.24 | 241 | <.0001 | 0.43 | 0.31 | 1.40 | 241 | 0.1635 |
| Pharmacists and pharmacy characteristics | ||||||||||||||||||||
| Sex of pharmacist | ||||||||||||||||||||
| Male | −0.07 | 0.04 | −1.73 | 243 | 0.0842 | −0.07 | 0.04 | −1.65 | 243 | 0.0995 | ||||||||||
| Female | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Age of pharmacist (years) | ||||||||||||||||||||
| ≤45 | 0.15 | 0.05 | 2.74 | 722 | 0.0064 | 0.15 | 0.05 | 2.70 | 722 | 0.0070 | ||||||||||
| 46–55 | 0.16 | 0.06 | 2.94 | 722 | 0.0034 | 0.16 | 0.06 | 2.88 | 722 | 0.0040 | ||||||||||
| 56–65 | 0.14 | 0.06 | 2.46 | 722 | 0.0142 | 0.14 | 0.06 | 2.42 | 722 | 0.0157 | ||||||||||
| ≥66 | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Length of operation | ||||||||||||||||||||
| ≤12 months | 0.41 | 0.06 | 6.88 | 454 | <.0001 | 0.41 | 0.06 | 6.87 | 454 | <.0001 | ||||||||||
| 13-24 months | 0.22 | 0.06 | 3.63 | 454 | 0.0003 | 0.22 | 0.06 | 3.62 | 454 | 0.0003 | ||||||||||
| ≥25 months | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Separation of drug prescribing and dispensing | ||||||||||||||||||||
| Exception | −0.18 | 0.25 | −0.72 | 93 | 0.4741 | −0.18 | 0.25 | −0.71 | 93 | 0.4813 | ||||||||||
| Application | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Period of exclusion for reformed program | ||||||||||||||||||||
| ≤18 months | −0.03 | 0.30 | −0.11 | 88 | 0.9134 | −0.03 | 0.30 | −0.12 | 88 | 0.9075 | ||||||||||
| ≥19 months | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Total drug purchase (10 million KRW) | 0.00 | 0.00 | 16.85 | 16,000 | <.0001 | 0.01 | 0.00 | 16.80 | 16,000 | <.0001 | ||||||||||
| Regional characteristics | ||||||||||||||||||||
| Region | ||||||||||||||||||||
| Metropolitan | −0.05 | 0.05 | −0.90 | 241 | 0.3677 | −0.02 | 0.05 | −0.34 | 241 | 0.7348 | ||||||||||
| Non-metropolitan | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Total number of clinics in regions with pharmacies | ||||||||||||||||||||
| ≤60 | −0.08 | 0.07 | −1.18 | 241 | 0.2392 | −0.07 | 0.07 | −1.10 | 241 | 0.2733 | ||||||||||
| ≥61 | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Total number of pharmacy in regions with pharmacies | ||||||||||||||||||||
| ≤45 | 0.04 | 0.06 | 0.63 | 241 | 0.5302 | 0.03 | 0.06 | 0.50 | 241 | 0.6175 | ||||||||||
| ≥46 | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Average of individual income in regions with pharmacies | ||||||||||||||||||||
| ≤38 million KRW | −0.01 | 0.06 | −0.14 | 241 | 0.8855 | −0.01 | 0.05 | −0.16 | 241 | 0.8746 | ||||||||||
| ≥39 million KRW | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Proportion of national basic livelihood security beneficiaries in regions with pharmacies | 0.01 | 0.02 | 0.75 | 241 | 0.4500 | 0.00 | 0.02 | −0.06 | 241 | 0.9499 | ||||||||||
| Random parta | Variance | SE | Z |
| Variance | SE | Z |
| Variance | SE | Z |
| Variance | SD | Z |
| ||||
| Variance of the intercept at the regional level | 0.04 | 0.01 | 3.40 | 0.0003 | 0.03 | 0.01 | 3.24 | 0.0006 | 0.04 | 0.01 | 3.45 | 0.0003 | 0.03 | 0.01 | 3.29 | 0.0005 | ||||
| Variance of the intercept at the pharmacy level | 5.76 | 0.06 | 90.23 | <.0001 | 5.64 | 0.06 | 90.20 | <.0001 | 5.76 | 0.06 | 90.22 | <.0001 | 5.64 | 0.06 | 90.19 | <.0001 | ||||
| ICC | 0.0061 | 0.0057 | 0.0064 | 0.0061 | ||||||||||||||||
Note. The results of multilevel linear regression analysis using mixed model to examine associations between program designation (i.e., exception region or application region) and percentages of drug consumption (antipyretic, analgesic, anti-inflammatory drugs, and psychotropic drugs, adrenal cortical hormones, and antibiotics) in hierarchical data which was consisted of pharmacy and regional levels. Significant level P < 0.05. If these values were lower than 0.05, it indicated that there were statistically significant associations between independent variable and drug consumption
Model 1 empty model, Model 2 only adjusted for pharmacy-level variables, Model 3 only adjusted regional-level variables, Model 4 fully adjusted
KRW Republic of Korea Won, ICC Intra-class Correlation Coefficient, the results were rounded to the second digit after the decimal point, df degrees of freedom
aIf p-value were lower than 0.05, it indicated that each level variable had statistically significant association with the outcome variables. The ICC was defined that the ratio of the between cluster variance to the total variance. It was interpreted as the correlation among observations within the same cluster
Results for multi-level analyses of the associations with percentages of drug consumption in Adrenal cortical hormones
| Variables | Adrenal cortical hormones | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | |||||||||||||||||
| β | SE | t | df |
| β | SE | t | df |
| β | SE | t | df |
| β | SE | t | df |
| |
| Intercept | 0.30 | 0.01 | 32.20 | 246 | <.0001 | 0.38 | 0.09 | 4.38 | 246 | <.0001 | 0.31 | 0.03 | 9.15 | 241 | <.0001 | 0.41 | 0.09 | 4.48 | 241 | <.0001 |
| Pharmacists and pharmacy characteristics | ||||||||||||||||||||
| Sex of pharmacist | ||||||||||||||||||||
| Male | 0.00 | 0.01 | −0.02 | 243 | 0.9876 | 0.00 | 0.01 | −0.19 | 243 | 0.8498 | ||||||||||
| Female | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Age of pharmacist (years) | ||||||||||||||||||||
| ≤45 | 0.04 | 0.02 | 2.25 | 722 | 0.0251 | 0.03 | 0.02 | 2.10 | 722 | 0.0361 | ||||||||||
| 46–55 | 0.00 | 0.02 | −0.21 | 722 | 0.8342 | −0.01 | 0.02 | −0.37 | 722 | 0.7139 | ||||||||||
| 56–65 | −0.02 | 0.02 | −0.93 | 722 | 0.3528 | −0.02 | 0.02 | −1.01 | 722 | 0.3152 | ||||||||||
| ≥66 | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Length of operation | ||||||||||||||||||||
| ≤12 months | 0.05 | 0.02 | 2.78 | 454 | 0.0057 | 0.05 | 0.02 | 2.74 | 454 | 0.0064 | ||||||||||
| 13–24 months | 0.03 | 0.02 | 1.92 | 454 | 0.0555 | 0.03 | 0.02 | 1.89 | 454 | 0.0595 | ||||||||||
| ≥25 months | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Separation of drug prescribing and dispensing | ||||||||||||||||||||
| Exception | 0.72 | 0.07 | 10.05 | 93 | <.0001 | 0.72 | 0.07 | 9.92 | 93 | <.0001 | ||||||||||
| Application | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Period of exclusion for reformed program | ||||||||||||||||||||
| ≤18 months | −0.10 | 0.09 | −1.16 | 88 | 0.2484 | −0.10 | 0.09 | −1.17 | 88 | 0.2442 | ||||||||||
| ≥19 months | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Total drug purchase (10 million KRW) | 0.00 | 0.00 | −3.68 | 16,000 | 0.0002 | 0.00 | 0.00 | −3.68 | 16,000 | 0.0002 | ||||||||||
| Regional characteristics | ||||||||||||||||||||
| Region | ||||||||||||||||||||
| Metropolitan | −0.06 | 0.02 | −3.00 | 241 | 0.0030 | −0.04 | 0.02 | −2.07 | 241 | 0.0395 | ||||||||||
| Non-metropolitan | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Total number of clinics in regions with pharmacies | ||||||||||||||||||||
| ≤60 | 0.01 | 0.03 | 0.24 | 241 | 0.8108 | −0.01 | 0.02 | −0.27 | 241 | 0.7887 | ||||||||||
| ≥61 | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Total number of pharmacy in regions with pharmacies | ||||||||||||||||||||
| ≤45 | 0.02 | 0.02 | 0.98 | 241 | 0.3303 | 0.01 | 0.02 | 0.50 | 241 | 0.6149 | ||||||||||
| ≥46 | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Average of individual income in regions with pharmacies | ||||||||||||||||||||
| ≤38 million KRW | 0.01 | 0.02 | 0.37 | 241 | 0.7088 | −0.01 | 0.02 | −0.31 | 241 | 0.7555 | ||||||||||
| ≥39 million KRW | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Proportion of national basic livelihood security beneficiaries in regions with pharmacies | 0.00 | 0.01 | −0.72 | 241 | 0.4740 | 0.00 | 0.01 | −0.52 | 241 | 0.6035 | ||||||||||
| Random parta | Variance | SE | Z |
| Variance | SE | Z |
| Variance | SE | Z |
| Variance | SD | Z |
| ||||
| Variance of the intercept at the regional level | 0.01 | 0.00 | 4.76 | <.0001 | 0.01 | 0.00 | 4.13 | <.0001 | 0.01 | 0.00 | 4.42 | <.0001 | 0.01 | 0.00 | 3.99 | <.0001 | ||||
| Variance of the intercept at the pharmacy level | 0.48 | 0.01 | 89.74 | <.0001 | 0.47 | 0.01 | 89.77 | <.0001 | 0.48 | 0.01 | 89.72 | <.0001 | 0.47 | 0.01 | 89.76 | <.0001 | ||||
| ICC | 0.0223 | 0.0151 | 0.0199 | 0.0149 | ||||||||||||||||
Note. The results of multilevel linear regression analysis using mixed model to examine associations between program designation (i.e., exception region or application region) and percentages of drug consumption (antipyretic, analgesic, anti-inflammatory drugs, and psychotropic drugs, adrenal cortical hormones, and antibiotics) in hierarchical data which was consisted of pharmacy and regional levels. Significant level P < 0.05. If these values were lower than 0.05, it indicated that there were statistically significant associations between independent variable and drug consumption
Model 1 = empty model, Model 2 = only adjusted for pharmacy-level variables, Model 3 = only adjusted regional-level variables, Model 4 = fully adjusted
KRW Republic of Korea Won, ICC Intra-class Correlation Coefficient, the results were rounded to the second digit after the decimal point. df degrees of freedom
aIf p-value were lower than 0.05, it indicated that each level variable had statistically significant association with the outcome variables. The ICC was defined that the ratio of the between cluster variance to the total variance. It was interpreted as the correlation among observations within the same cluster
Results for multi-level analyses of the associations with percentages of drug consumption in Antibiotics
| Variables | Antibiotics | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | |||||||||||||||||
| β | SE | t | df |
| β | SE | t | df |
| β | SE | t | df |
| β | SE | t | df |
| |
| Intercept | 7.00 | 0.18 | 39.29 | 246 | <.0001 | 6.56 | 2.83 | 2.31 | 246 | 0.0216 | 7.72 | 0.62 | 12.51 | 241 | <.0001 | 7.29 | 2.90 | 2.52 | 241 | 0.0125 |
| Pharmacists and pharmacy characteristics | ||||||||||||||||||||
| Sex of pharmacist | ||||||||||||||||||||
| Male | 0.08 | 0.36 | 0.23 | 243 | 0.8207 | 0.17 | 0.37 | 0.45 | 243 | 0.6551 | ||||||||||
| Female | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Age of pharmacist (years) | ||||||||||||||||||||
| ≤45 | 3.49 | 0.51 | 6.78 | 722 | <.0001 | 3.42 | 0.52 | 6.58 | 722 | <.0001 | ||||||||||
| 46–55 | 2.35 | 0.52 | 4.49 | 722 | <.0001 | 2.24 | 0.53 | 4.25 | 722 | <.0001 | ||||||||||
| 56–65 | 1.22 | 0.55 | 2.24 | 722 | 0.0255 | 1.12 | 0.55 | 2.05 | 722 | 0.0404 | ||||||||||
| ≥66 | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Length of operation | ||||||||||||||||||||
| ≤12 months | 2.02 | 0.57 | 3.58 | 454 | 0.0004 | 2.02 | 0.57 | 3.57 | 454 | 0.0004 | ||||||||||
| 13–24 months | 0.27 | 0.58 | 0.47 | 454 | 0.6417 | 0.25 | 0.58 | 0.44 | 454 | 0.6632 | ||||||||||
| ≥25 months | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Separation of drug prescribing and dispensing | ||||||||||||||||||||
| Exception | −1.49 | 2.35 | −0.63 | 93 | 0.5283 | −1.55 | 2.35 | −0.66 | 93 | 0.5134 | ||||||||||
| Application | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Period of exclusion for reformed program | ||||||||||||||||||||
| ≤18 months | −0.27 | 2.81 | −0.10 | 88 | 0.9240 | −0.45 | 2.81 | −0.16 | 88 | 0.8720 | ||||||||||
| ≥19 months | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Total drug purchase (10 million KRW) | −0.02 | 0.00 | −7.93 | 16,000 | <.0001 | −0.02 | 0.00 | −7.63 | 16,000 | <.0001 | ||||||||||
| Regional characteristics | ||||||||||||||||||||
| Region | ||||||||||||||||||||
| Metropolitan | −0.03 | 0.39 | −0.07 | 241 | 0.9466 | −0.02 | 0.39 | −0.04 | 241 | 0.9659 | ||||||||||
| Non-metropolitan | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Total number of clinics in regions with pharmacies | ||||||||||||||||||||
| ≤60 | −0.31 | 0.49 | −0.62 | 241 | 0.5331 | −0.30 | 0.49 | −0.61 | 241 | 0.5409 | ||||||||||
| ≥61 | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Total number of pharmacy in regions with pharmacies | ||||||||||||||||||||
| ≤45 | 0.85 | 0.46 | 1.86 | 241 | 0.0646 | 0.55 | 0.46 | 1.21 | 241 | 0.2270 | ||||||||||
| ≥46 | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Average of individual income in regions with pharmacies | ||||||||||||||||||||
| ≤38 million KRW | −0.54 | 0.41 | −1.31 | 241 | 0.1917 | −0.30 | 0.41 | −0.75 | 241 | 0.4568 | ||||||||||
| ≥39 million KRW | Ref | - | - | Ref | - | - | Ref | - | - | Ref | - | - | ||||||||
| Proportion of national basic livelihood security beneficiaries in regions with pharmacies | −0.26 | 0.14 | −1.94 | 241 | 0.0537 | −0.19 | 0.14 | −1.42 | 241 | 0.1584 | ||||||||||
| Random parta | Variance | SE | Z |
| Variance | SE | Z |
| Variance | SE | Z |
| Variance | SD | Z |
| ||||
| Variance of the intercept at the regional level | 0.06 | 0.40 | 0.15 | 0.4411 | 4.02 | 33759544.00 | 0.00 | 0.5000 | 0.10 | 0.39 | 0.25 | 0.4014 | 0.05 | 0.38 | 0.14 | 0.4462 | ||||
| Variance of the intercept at the pharmacy level | 516.25 | 5.71 | 90.49 | <.0001 | 511.21 | 5.64 | 90.68 | <.0001 | 515.85 | 5.70 | 90.50 | <.0001 | 511.09 | 5.65 | 90.48 | <.0001 | ||||
| ICC | 0.0001 | 0.0078 | 0.0002 | 0.0001 | ||||||||||||||||
Note. The results of multilevel linear regression analysis using mixed model to examine associations between program designation (i.e., exception region or application region) and percentages of drug consumption (antipyretic, analgesic, anti-inflammatory drugs, and psychotropic drugs, adrenal cortical hormones, and antibiotics) in hierarchical data which was consisted of pharmacy and regional levels. Significant level P < 0.05. If these values were lower than 0.05, it indicated that there were statistically significant associations between independent variable and drug consumption
Model 1 = empty model, Model 2 = only adjusted for pharmacy-level variables, Model 3 = only adjusted regional-level variables, Model 4 = fully adjusted
KRW Republic of Korea Won, ICC Intra-class Correlation Coefficient, the results were rounded to the second digit after the decimal point, df degrees of freedom
aIf p-value were lower than 0.05, it indicated that each level variable had statistically significant association with the outcome variables. The ICC was defined that the ratio of the between cluster variance to the total variance. It was interpreted as the correlation among observations within the same cluster
Fig. 2Results of the sub-group analysis on the relationships between drug prescribing and dispensing exception and application regions and drug consumption, by sex and age of the pharmacists. *Statistically significant difference, multilevel linear regression analysis using mixed model. aThe results of the sub-group analysis by sex of pharmacist, (Male) Antipyretic; Analgesic; Anti-inflammatory drugs = t: 2.76, degrees of freedom (df): 80, p-value: 0.0071; Psychotropic drugs = t: −1.11, df: 80, p-value: 0.2721; Adrenal cortical hormones = t: 8.60, df: 80, p-value <0.0001; Antibiotics = t:-0.42, df: 80, p-value: 0.6789. (Female) Antipyretic; Analgesic; Anti-inflammatory drugs = t: 2.36, df: 48, p-value: 0.0224; Psychotropic drugs = t: 0.18, df: 48, p-value: 0.8608; Adrenal cortical hormones = t: 4.77, df: 48, p-value < 0.0001; Antibiotics = t: −1.37, df: 48, p-value: 0.1756. bThe results of the sub-group analysis by age of pharmacist, (Less than 45 years) Antipyretic; Analgesic; Anti-inflammatory drugs = t: 0.49, df: 21, p-value: 0.6292; Psychotropic drugs = t: 0.41, df: 21, p-value: 0.6878; Adrenal cortical hormones = t: 2.87, df: 21, p-value: 0.0092; Antibiotics = t: −0.46, df: 21, p-value: 0.6475. (46–55 years) Antipyretic; Analgesic; Anti-inflammatory drugs = t: 2.44, df: 37, p-value: 0.0194; Psychotropic drugs = t: −0.85, df: 37, p-value: 0.4020; Adrenal cortical hormones = t: 2.78, df: 37, p-value: 0.0085; Antibiotics = t: −2.11, df: 37, p-value: 0.0415. (56–65 years) Antipyretic; Analgesic; Anti-inflammatory drugs = t: 1.80, df: 48, p-value < 0.001; Psychotropic drugs = t: −0.50, df: 48, p-value: 0.6207; Adrenal cortical hormones = t: 6.26, df: 48, p-value < .0001; Antibiotics = t: −0.72, df: 48, p-value: 0.4739. (More than 65 years) Antipyretic; Analgesic; Anti-inflammatory drugs = t: 3.70, df: 63, p-value: 0.0005; Psychotropic drugs = t: −0.51, df: 63, p-value: 0.6134; Adrenal cortical hormones = t: 6.05, df: 63, p-value < 0.0001; Antibiotics = t: −0.29, df: 63, p-value: 0.7746
Fig. 3Results of the sub-group analysis on the relationships between drug prescribing and dispensing exception regions and drug consumption, by region and time since pharmacy operation. *Statistically significant difference, multilevel linear regression analysis using mixed model. aThe results of the sub-group analysis by pharmacy region, (Metropolitan) Antipyretic; Analgesic; Anti-inflammatory drugs = t: 0.11, df: 6, p-value: 0.9173; Psychotropic drugs = t: −0.44, df: 6, p-value: 0.6755; Adrenal cortical hormones = t: 3.17, df: 6, p-value: 0.0194; Antibiotics = t: −0.08, df: 6, p-value: 0.9388. (Non-metropolitan) Antipyretic; Analgesic; Anti-inflammatory drugs = t: 3.47, df: 86, p-value: 0.0008; Psychotropic drugs = t: −1.11, df: 86, p-value: 0.2710; Adrenal cortical hormones = t: 8.67, df: 86, p-value < 0.0001; Antibiotics = t: −0.40, df: 86, p-value: 0.6922. bThe results of the sub-group analysis by time since pharmacy operation, (Less than 12 months) Antipyretic; Analgesic; Anti-inflammatory drugs = t: 1.68, df: 23, p-value: 0.1061; Psychotropic drugs = t: −0.58, df: 23, p-value: 0.5694; Adrenal cortical hormones = t: 6.85, df: 23, p-value < 0.0001; Antibiotics = t: −0.35, df: 23, p-value: 0.7317. (13–24 months) Antipyretic; Analgesic; Anti-inflammatory drugs = t: 3.08, df: 25, p-value: 0.0050; Psychotropic drugs = t: −0.40, df: 25, p-value: 0.6932; Adrenal cortical hormones = t: 3.31, df: 25, p-value: 0.0029; Antibiotics = t: −2.49, df: 25, p-value: 0.0196. (More than 25 months) Antipyretic; Analgesic; Anti-inflammatory drugs = t: −0.56, df: 86, p-value: 0.5798; Psychotropic drugs = t: −0.26, df: 86, p-value: 0.7928; Adrenal cortical hormones = t: 0.79, df: 86, p-value: 0.4337; Antibiotics = t: −0.40, df: 86, p-value: 0.6922